Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-23T20:51:05.483Z Has data issue: false hasContentIssue false
  • English
  • Français

Current Status of Levodopa Therapy in Idiopathic Parkinson's Disease

Published online by Cambridge University Press:  05 January 2016

S. Gauthier  and
L. Gauthier
S. Gauthier*
Affiliation:
McGill Centre for Studies in Age and Aging and the School of Physical and Occupational Therapy, McGill University
L. Gauthier
Affiliation:
McGill Centre for Studies in Age and Aging and the School of Physical and Occupational Therapy, McGill University
*
McGill Centre for Studies in Age and Aging,1650 Cedar Ave., Montréal, Québec, Canada H3G 1A4
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Levodopa is currently used at all stages of Parkinson's disease, particularly from Stage 3 onward. Most patients start levodopa within four years of the onset of disease, earlier in the akineto-rigid patients (average delay of 2.1 years) than in those where resting tremor predominates (average delay of 3.4 years). Advanced age (>80) is no deterrent to the use of levodopa if required. Wearing off is most noticeable in Stage 3 or after 10 years of therapy with levodopa. An inverse correlation was found between age and wearing off, suggesting a marked sensitivity of younger patients to levodopa. Future studies on the use of dopamine agonists should thus be stratified according to age.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue S3 , August 1987 , pp. 452 - 454
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

REFERENCES

1.Muenter, MD. Should levodopa therapy be started early or late? Can J Neurol Sci 1984; 11: 195–199.CrossRefGoogle ScholarPubMed
2.Fahn, S, Bressman, SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984; 11: 200–206.CrossRefGoogle ScholarPubMed
3.Kofman, OS. Are levodopa “drug holidays” justified? Can J Neurol Sci 1984; 11: 206–209.CrossRefGoogle ScholarPubMed
4.Calne, DB, Rinne, UK. Controversies in the management of Parkinson’s disease. Mov Dis 1986; 1: 159–162.CrossRefGoogle ScholarPubMed
5.Guttman, M, Seeman, P, Reynolds, GP, et al. Dopamine D2 receptor density remains constant in treated Parkinson’s disease. Ann Neurol 1986; 19: 487–492.CrossRefGoogle ScholarPubMed
6.Mayeux, R, Stern, Y, Mulvey, K, Cote, L. Reappraisal of temporary levodopa withdrawal (“drug holiday”) in Parkinson’s disease.? Engl J. Med 1985; 313: 724–728.CrossRefGoogle ScholarPubMed
7.Hoehn, MM, Yahr, MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442.CrossRefGoogle ScholarPubMed
8.Barbeau, A, Roy, M. Familial subsets in idiopathic Parkinson’s disease. Can J Neurol Sci 1984; 11: 144–150.CrossRefGoogle ScholarPubMed
9.Parkes, JD. Domperidone and Parkinson’s disease. Clin Neuropharmacol 1986; 9: 517–532.CrossRefGoogle ScholarPubMed
10.Rinne, UK. Combined bromocriptine-levodopa therapy early in Parkinson’s disease. Neurology 1985; 35: 1196–1198.CrossRefGoogle ScholarPubMed
11.Lang, AE, Meadows, JC, Parkes, JD, Marsden, CD. Early onset of the “on-off” phenomenon in children with symptomatic parkinsonism. J Neurol Neurosurg Psychiatry 1982; 45: 823–825.CrossRefGoogle ScholarPubMed
12.Langston, JW, Ballard, P. Parkinsonism induced by MPTP: implications for treatment and pathogenesis of Parkinson’s disease. Can J Neurol Sci 1984; 11: 160–165.CrossRefGoogle ScholarPubMed
13.Nutt, JG, Woodward, WR, Hammerstad, JP, et al. The “on-off” phenomenon in Parkinson’s disease.? Engl J Med 1984; 310: 483–488.CrossRefGoogle Scholar
14.Kurlan, R, Rubin, AJ, Miller, C, et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986; 20: 262–265.CrossRefGoogle ScholarPubMed